- Home
- BOOT vs RNA Comparison
BOOT vs RNA Comparison
Compare BOOT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BOOT | RNA |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 222.5M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BOOT | RNA |
|---|---|---|
| Price | $166.72 | $12.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | ★ $223.09 | $69.26 |
| AVG Volume (30 Days) | ★ 726.1K | 111.7K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $776,854,000.00 | N/A |
| Revenue This Year | $19.98 | $88.12 |
| Revenue Next Year | $13.91 | $18.11 |
| P/E Ratio | $72.40 | ★ N/A |
| Revenue Growth | ★ 14.59 | N/A |
| 52 Week Low | $133.18 | $11.13 |
| 52 Week High | $210.25 | $73.06 |
Technical Indicators
Market Signals| Indicator | BOOT | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 52.55 |
| Support Level | $158.75 | $11.95 |
| Resistance Level | $170.63 | $14.05 |
| Average True Range (ATR) | 6.42 | 0.35 |
| MACD | 2.07 | 0.12 |
| Stochastic Oscillator | 83.40 | 80.44 |
Price Performance
Historical ComparisonAbout BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores that sell western and work boots and related apparel and accessories. The Company operates retail locations throughout the U.S. and sells its merchandise via the Internet. The Company operates a total of approximately 539 stores in 49 states. All stores operated under the Boot Barn name.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.